Le Lézard
Classified in: Health, Covid-19 virus
Subjects: NPT, EXE, AVO

ASTHO Statement on Easing Public Health Measures Amid COVID-19 Outbreak


ARLINGTON, Va., March 27, 2020 /PRNewswire/ -- Michael Fraser, chief executive officer of the Association of State and Territorial Health Officials (ASTHO), issued the following statement today in response to the ongoing national discussion about when to end or ease public health measures to reduce the risk of COVID-19 transmissions.

"Like all Americans, our nation's state and territorial public health leaders are looking forward to ending and/or easing current restrictions on mass gatherings, non-essential business closures, social distancing, and other measures that have drastically impacted the lives of so many. As federal leaders look to reduce or ease emergency restrictions and create 'risk categories' for COVID-19 transmission, we believe they should consider the following measures.

Decisions to end or ease restrictions should:

Decisions to reduce or end restrictions on mass gatherings and social distancing will differ based on state and regional factors, including the prevalence of COVID-19, population density, healthcare system capacity, and the rate of community transmission in different states and territories. As such, federal public health officials and the administration must work collaboratively with states and territories to develop guidelines that prioritize evidence-based decisions on when and how to ease or end restrictions for specific jurisdictions.

The use of designations 'low-risk,' 'medium-risk,' or 'high-risk' may be misleading when used in the context of an acute infectious disease that can quickly be transmitted person to person. This could create a false sense of security in a community designated 'low-risk' while also creating fear and reinforcing stigma in an area deemed 'high-risk.' Many factors influence disease transmission; as we have seen nationally, an asymptomatic COVID-19 positive traveler who enters a community may quickly spread the virus unintentionally, which could change the risk designation within a single day."

ASTHO is the national nonprofit organization representing the public health agencies of the United States, the U.S. territories, and the District of Columbia, as well as the more than 100,000 public health professionals these agencies employ. ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in state-based public health practice.

SOURCE Association of State and Territorial Health Officials


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: